Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; Implication of immunologic and metabolic effects of a jak-stat pathway inhibitor

Journal of Clinical Immunology

Volumn 32, Issue 5, 2012, Pages 1038-1047

  Davoodi Semiromi, Abdoreza ^a,c   Hassanzadeh, Azadeh ^a   Wasserfall, Clive H ^b   Droney, Andrew ^a   Atkinson, Mark ^b  

^a Department of Pharmacotherapy and Translational Research   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AG490; NOD; Regulatory T cell; Type 1 diabetes; Tyrosine kinase inhibitor

Indexed keywords

DIMETHYL SULFOXIDE; GLUCOSE; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; ROSIGLITAZONE; STAT PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DIABETES CONTROL; DIABETOGENESIS; DISEASE COURSE; DNA BINDING; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENE; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; MACROPHAGE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PPAR GAMMA GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BLOOD GLUCOSE; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; PPAR GAMMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; STAT TRANSCRIPTION FACTORS; TYRPHOSTINS;

EID: 84866730597     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9707-y     Document Type: Article

References (40)

1. Augstein P, Dunger A, Heinke P, Wachlin G, Berg S, Hehmke B, Salzsieder E. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun. 2003; 304:378-84.
2. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006; 312:1175-8.
3. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol. 1998; 357:221-5.
4. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, Verani R, Kahan BD, Stepkowski SM, Kirken RA. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol. 2001; 166:3724-32.
5. Bright JJ, Du C, Sriram S. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol. 1999; 162:6255-62.
6. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 2002; 1:893-9.
7. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302:875-8.
8. Chauhan G, Spurgeon CJ, Tabassum R, Bhaskar S, Kulkarni SR, Mahajan A, Chavali S, Kumar MV, Prakash S, Dwivedi OP, Ghosh S, Yajnik CS, Tandon N, Bharadwaj D, Chandak GR. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes. 2010; 59:2068-74.
9. Constantin G, Brocke S, Izikson A, Laudanna C, Butcher EC. Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur J Immunol. 1998; 28:3523-9.
10. Constantin G, Laudanna C, Brocke S, Butcher EC. Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor. J Immunol. 1999; 162:1144-9.
11. Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J. Clin. Immunol. 2011
12. Davoodi-Semiromi A, Laloraya M, Kumar GP, Purohit S, Jha RK, She JX. A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice. J Biol Chem. 2004; 279:11553-61.
13. Davoodi-Semiromi A, McDuffie M, Litherland S, Clare-Salzler M. Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem Biophys Res Commun. 2007; 11; 356(3):655-61.
14. Davoodi-Semiromi A, Cheikhi A, Xia C, Litherland S, Clare-Salzler M. Modulation of CD4+Foxp3-T-cells with a JAK-STAT5 kinase inhibitor. J Immunol. 2007; 178:S237-c.
15. Davoodi-Semiromi A, Copper-DeHoff R. Note to readers on: long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem. Pharmacol. Biochem Pharmacol. 2012; 15; 83(6):821.
16. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998; 20:284-7.
17. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, Nissen MH, Ropke C, Wasik MA, Odum N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001; 15:787-93.
18. Fischer-Posovszky P, Newell FS, Wabitsch M, Tornqvist HE. Human SGBS cells - a unique tool for studies of human fat cell biology. Obes Facts. 2008; 1:184-9.
19. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011; 186:4234-43.
20. Goncalves S, Fernandez-Sanchez R, Sanchez-Nino MD, Tejedor A, Neria F, Egido J, Ruiz-Ortega M, Ortiz A. Tyrphostins as potential therapeutic agents for acute kidney injury. Curr Med Chem. 2010; 17:974-86.
21. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2007; 21:618-28.
22. Higuchi T, Shiraishi T, Shirakusa T, Hirayama S, Shibaguchi H, Kuroki M, Hiratuka M, Yamamoto S, Iwasaki A, Kuroki M. Prevention of acute lung allograft rejection in rat by the janus kinase 3 inhibitor, tyrphostin AG490. J Heart Lung Transplant. 2005; 24:1557-64.
23. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011; 25:201-10.
24. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol. 1999; 65:891-9.
25. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol. 2000; 165:5097-104.
26. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol. 2008; 181:6955-63.
27. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008; 105:18895-900.
28. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996; 379:645-8.
29. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond). 2010; 118:241-7.
30. Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, Stevens HE, Todd JA. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009; 52:2109-16.
31. Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC. Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine. 2009; 46:65-71.
32. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med. 1998; 339:953-9.
33. Schmidt-Supprian M, Tian J, Grant EP, Pasparakis M, Maehr R, Ovaa H, Ploegh HL, Coyle AJ, Rajewsky K. Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A. 2004; 101:4566-71.
34. Sidhu M, Cotoner CA, Guleng B, Arihiro S, Chang S, Duncan KW, Ajami AM, Chau M, Reinecker HC. Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. Inflamm. Bowel. Dis. 2011
35. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008; 9:194-202.
36. Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E, Debatin KM, Hauner H. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord. 2001; 25:8-15.
37. Winkler C, Raab J, Grallert H, Ziegler AG. Lack of association of type 2 diabetes susceptibility genotypes and body weight on the development of islet autoimmunity and type 1 diabetes. PLoS One. 2012; 7:e35410.
38. Yaacob NS, Kaderi MA, Norazmi MN. Differential transcriptional expression of PPARalpha, PPARgamma1, and PPARgamma2 in the peritoneal macrophages and T-cell subsets of non-obese diabetic mice. J Clin Immunol. 2009; 29:595-602.
39. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010; 28:3965-72.
40. Zhang F, Zhang Q, Tengholm A, Sjoholm A. Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion. Am J Physiol Cell Physiol. 2006; 291:C466-75.